New Harris Poll Reveals ASCO Conference and Health Equity Key Topics Amongst Influential Oncologists
New data from The Harris Poll reveals that two things have been top in the minds of leading oncologists: ASCO [...]
National Health Alliance Panel: Centering Patient Needs in Value-Based Oncology
Considering patient needs in oncology care means thinking beyond just health outcomes, according to a panel of oncology experts speaking [...]
Clovis Withdraws Approval Applications for Ovarian Cancer Drug Rubraca
Clovis Oncology has announced it will withdraw its FDA approval application for Rubraca, its third-line BRCA-mutated ovarian cancer drug. The [...]
BeiGene’s Leukemia Drug FDA Decision Delayed
In a temporary win for AbbVie and Johnson & Johnson’s chronic lymphocytic leukemia (CLL) drug Imbruvica, the FDA has extended [...]
Tackling Childhood Cancer Through Bioengineering Approaches
Childhood cancer is a leading killer of children and teens in the United States. Unfortunately, clinical and preclinical trials for [...]
High US Cancer Care Prices Don’t Reduce Patient Mortality
The US spends double on cancer care than other high-income nations but sees only modest improvements in mortality, according to [...]
Top Pharma Companies Form Coalition to Increase Access to Cancer Therapies in Developing Countries
Less than half of the cancer therapies deemed essential by the World Health Organization are available in low- and lower-middle-income [...]
Bayer Backs Out of Atara CAR-T Partnership
Following a pause in a CAR-T cell mesothelioma therapy caused by a patient death, Bayer has pulled out of a [...]
Gilead Partners with Dragonfly to Investigate Natural Killer Cell Therapeutics
Gilead has announced a $300 billion deal with Dragonfly Therapeutics to advance natural killer (NK) cell therapy for use in [...]
Roche’s Oral Breast Cancer Drug Disappoints in Phase II Study
The pharma manufacturer Roche has announced discouraging results for its oral breast cancer drug giredestrant. Results show that the drug [...]
The Netherlands Invests €325 into Patient-Centered Preclinical Oncology Drug Development
The Dutch National Growth Fund has announced it’s investing €325 ($351 million) into preclinical oncology drug development through the Oncode-Pact [...]
ISPOR Webinar: Accelerating Patient Access to Next Generation Sequencing
The future of personalized oncology care depends on next-generation sequencing (NGS). However, the adoption of this technology is held back [...]
Webinar Series: ResearchX Season ’22
This years’ Flatiron ResearchX series has focused on the impact of evidence generation innovations on oncology research and care. Previous [...]
Study: COVID-19 Outcomes Worse Among Black Cancer Patients Compared to White Cancer Patients
Health disparities have been brought to the forefront due to the COVID-19 pandemic. In a new study published in JAMA [...]
FDA Oncology Chief Denies Claims that Rejection of Lilly and Innovent Cancer Drug is Politically Motivated
On the heels of the FDA’s rejection of Eli Lilly and Innovent Biologics’ low-cost lung cancer immunotherapy drug sintilimab, the [...]
Biden Proposes $2.1 Billion in FDA Funding for Pandemic Preparedness and Cancer Moonshot
As the Biden administration attempts to ramp up funding for public health and biomedical science efforts, it has now proposed [...]
Interview with SGO President: Diverse Gynecologic Oncologists Improve Health Outcomes
In a new Pharmacy Times interview, S. Diane Yamada, MD, President of the Society of Gynecologic Oncology (SGO), discusses the [...]
Free Cytel E-book – The Fundamentals of Real World Evidence in Oncology Drug Development
As real-world evidence (RWE) is increasingly utilized for drug pricing and reimbursement decision, the potential for RWE to drive drug [...]
Final Clinical Cancer Trial Guidances Issued By FDA
Three new final guidances for cancer trials have been released by the US Food and Drug Administration (FDA), which build [...]
Biospark Partners with xCures to Advance New Oncology Real World Dataset
Biospark and xCures have announced a new partnership to develop and release a new dataset comprised of outcomes data from [...]
Whitepaper: What the New FDA Guidelines Mean for Patient-Reported Outcomes in Oncology Trials
The FDA has just released its draft guidance on oncology clinical trials using patient reported outcome measures (PROMS). The guidance [...]
23andMe Begins Clinical Trial for Their First Drug
Clinical trials have begun for the now-ubiquitous DNA-testing company 23andMe’s new cancer drug. The immuno-oncology antibody, named 23ME-000610, targets solid [...]
Webinar: Strategies to Overcome CAR-T Cell Resistance During Cell Therapy
CAR-T cell therapy has shown great potential in certain lymphoma and leukemia patients. However, resistance to the CAR-T cells in [...]
Insider Trading Charges Filed Against University of Chicago Professor
University of Chicago professor Daniel Catenacci, MD has been charged with insider trading regarding his actions during a phase [...]
Oncology Care Model Reduces Medicare Costs for Cancer Treatment
A study evaluating the benefits of the Oncology Care Model, an alternate payment model for Medicare beneficiaries with cancer, found [...]
